vs
Side-by-side financial comparison of SILICOM LTD. (SILC) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $61.9M, roughly 1.1× SILICOM LTD.). SILICOM LTD. runs the higher net margin — -18.5% vs -49.0%, a 30.5% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 6.6%). SILICOM LTD. produced more free cash flow last quarter ($-3.3M vs $-84.7M).
Silicom Ltd. is a publicly traded company, headquartered in Israel, that specializes in the design, manufacture and marketing of connectivity solutions for a range of servers and server-based systems. Its shares are listed on the NASDAQ Global Market and on the Tel Aviv Stock Exchange. Silicom is a member of the RAD Group family of companies.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
SILC vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.9M | $70.6M |
| Net Profit | $-11.5M | $-34.6M |
| Gross Margin | 30.6% | — |
| Operating Margin | -19.8% | -56.7% |
| Net Margin | -18.5% | -49.0% |
| Revenue YoY | 6.6% | 81958.1% |
| Net Profit YoY | 16.3% | 54.9% |
| EPS (diluted) | $-2.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.9M | — | ||
| Q3 25 | — | $70.6M | ||
| Q4 24 | $58.1M | — |
| Q4 25 | $-11.5M | — | ||
| Q3 25 | — | $-34.6M | ||
| Q4 24 | $-13.7M | — |
| Q4 25 | 30.6% | — | ||
| Q3 25 | — | — | ||
| Q4 24 | 28.6% | — |
| Q4 25 | -19.8% | — | ||
| Q3 25 | — | -56.7% | ||
| Q4 24 | -22.8% | — |
| Q4 25 | -18.5% | — | ||
| Q3 25 | — | -49.0% | ||
| Q4 24 | -23.6% | — |
| Q4 25 | $-2.01 | — | ||
| Q3 25 | — | — | ||
| Q4 24 | $-2.28 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $42.1M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $117.5M | $503.0M |
| Total Assets | $152.2M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | — | ||
| Q3 25 | — | $490.9M | ||
| Q4 24 | $72.1M | — |
| Q4 25 | $117.5M | — | ||
| Q3 25 | — | $503.0M | ||
| Q4 24 | $127.8M | — |
| Q4 25 | $152.2M | — | ||
| Q3 25 | — | $577.1M | ||
| Q4 24 | $150.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.2M | $-84.6M |
| Free Cash FlowOCF − Capex | $-3.3M | $-84.7M |
| FCF MarginFCF / Revenue | -5.4% | -120.1% |
| Capex IntensityCapex / Revenue | 1.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.2M | — | ||
| Q3 25 | — | $-84.6M | ||
| Q4 24 | $18.3M | — |
| Q4 25 | $-3.3M | — | ||
| Q3 25 | — | $-84.7M | ||
| Q4 24 | $17.4M | — |
| Q4 25 | -5.4% | — | ||
| Q3 25 | — | -120.1% | ||
| Q4 24 | 29.9% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | — | 0.2% | ||
| Q4 24 | 1.6% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
